-
Servier and Dana-Farber Launch SHINEDoc Program, Enroll First PhD Student
•
French pharmaceutical company Servier and the US-based Dana-Farber Cancer Institute have announced the start of the Servier-funded SHINEDoc program in the United States, with the enrollment of the first PhD student from Dana-Farber. The program, which is set to begin this month, marks a significant step in fostering innovation in…
-
Thermo Fisher’s Oncomine Dx Target Test Gets FDA Green Light as Companion Diagnostic for Servier’s Voranigo
•
US pharmaceutical and biotechnology company Thermo Fisher Scientific (NYSE: TMO) has received marketing approval from the US Food and Drug Administration (FDA) for its Ion Torrent Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients eligible for treatment with Servier Pharmaceuticals’ Voranigo (vorasidenib) tablets. Voranigo, the first…
-
Servier and HUST Forge Partnership to Cultivate Innovative Therapies through SHINEDocs Program
•
French pharmaceutical company Servier has joined forces with Huazhong University of Science and Technology (HUST), a leading academic institution in China, to include HUST’s PhD students in the Servier Highlighting Innovation through its NEtwork of PhD students and Post-Docs (SHINEDocs) program. This strategic partnership aims to bridge the gap between…
-
Servier’s Voranigo Receives FDA Nod for IDH Inhibitor as Brain Tumor Treatment
•
The U.S. Food and Drug Administration (FDA) has granted first-time approval for Voranigo (vorasidenib), a therapy developed by Servier Pharmaceutical plc. Voranigo, an inhibitor of isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2), has been approved for the treatment of adult and pediatric patients aged 12 years and older with Grade…
-
Servier Faces $475 Million Penalty Over Banned Antidiabetic Drug Mediator in France
•
French pharmaceutical company Servier has been ordered by a French court to pay €430.6 million ($475 million) in a partial reversal of a 2021 decision concerning its now-banned antidiabetic drug, Mediator (benfluorex). The new ruling has found Servier guilty of fraud, improper acquisition of regulatory authorizations, aggravated deception, and involuntary…
-
CStone Pharmaceuticals Regains Exclusive Rights to Tibsovo in Greater China and Singapore
•
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced an agreement with French pharmaceutical company Servier that returns exclusive development, manufacturing, and commercialization rights to Tibsovo (ivosidenib) in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan, as well as Singapore. Originally developed by US-based Agios Pharmaceuticals,…
-
Servier’s Tibsovo Receives FDA Approval for IDH1-Mutated R/R MDS, Expanding Indications
•
France-based pharmaceutical company Servier has announced that the US Food and Drug Administration (FDA) has granted market approval for its drug Tibsovo (ivosidenib) for the treatment of recurrent or refractory (R/R) myelodysplastic syndrome (MDS) with IDH1 mutation. This marks the fifth indication for the drug in the IDH1 mutant cancer…
